Research reportCanadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.: III. Pharmacotherapy
Introduction
The Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatments (CANMAT), a not-for-profit scientific and educational organization, collaborated on the publication in 2001 of evidence-based clinical guidelines for the treatment of depressive disorders (Kennedy and Lam, 2001). A revision of these guidelines was undertaken by CANMAT in 2008–2009 to update the recommendations based on new evidence. The scope of these guidelines encompasses the management of adults with unipolar major depressive disorder (MDD). This section on Pharmacotherapy is one of 5 guideline articles. There are separate CANMAT guidelines for bipolar disorder (Yatham et al., 2009).
Pharmacotherapy remains the most studied and best evidenced treatment for MDD. Since 2000, at least 225 RCTs, 145 meta-analyses and 3 major systematic reports have been published on antidepressant medications for MDD. Despite this proliferation of data, it is widely recognized that the methodology of RCTs for antidepressants (including strict inclusion/exclusion criteria, intensive and frequent contact, short study duration, etc.), which are primarily conducted by pharmaceutical companies for registration of new medications, may not reflect real world clinical practice (Kennedy and Lam, 2001). While the past few years have also seen the emergence of larger scale effectiveness trials to address real-world generalizability, such as the U.S. Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial (Rush et al., 2004), these trials are still limited by many methodological deficiencies and some of the most important clinical questions remain unanswered. Hence, the recommendations are presented as guidance for clinicians who should consider them in the context of individual patients, and not as standards of care.
Section snippets
Methods
The full methods have been described elsewhere (Kennedy et al., 2009b) but, in summary, relevant English language studies published from January 1, 2000 to December 31, 2008 were identified using computerized searches of electronic databases (PubMed, PsychInfo, Cochrane Register of Clinical Trials), inspection of bibliographies, and review of other guidelines and major reports. The question–answer format of the previous guidelines has been retained based on feedback from clinicians.
What are the principles of pharmacotherapy management?
General principles of treatment with pharmacotherapy are similar to those for other treatment modalities for depression (Patten et al., 2009). Table 2 summarizes these principles, as adapted for pharmacotherapy. Adherence deserves special attention because early discontinuation rates of antidepressants are high. Although clinical practice guidelines recommend that the minimum duration of antidepressant treatment for MDD should be 6–12 months, about 30% of patients discontinue medications within
How long do you wait for a clinical response?
Most clinical trials define “clinical response” as ≥50% reduction in the score on a depression rating scale and “clinical remission” as a score within the “normal range” of the scale. Clinical lore states that the lag time for antidepressant therapeutic effects may be 2–4 weeks or longer. However, recent studies have shown an earlier onset of action, especially in those patients who eventually respond. Several recent meta-analyses concluded that onset of antidepressant effect can occur within 1–2
Which antidepressants can be used during pregnancy?
Since the previous guidelines in 2001, there have been no RCTs evaluating the safety and efficacy of antidepressants during pregnancy. The evidence remains limited to small studies or case control/cohort designs, often with many confounding variables and conflicting results. For example, comparison groups usually include women who are not using antidepressants but who are not necessarily depressed, so potential adverse effects associated with depression itself are not taken into account (Table
Role of funding source
These guidelines were entirely funded with internal funding from the Canadian Network for Mood and Anxiety Treatments; no external funds were sought or received.
Conflict of interest
RWL is on Speaker/Advisory Boards for, or has received research funds from: Advanced Neuromodulation Systems Inc., AstraZeneca, BrainCells Inc., Biovail, Canadian Institutes of Health Research, Canadian Network for Mood and Anxiety Treatments, Canadian Psychiatric Research Foundation, Eli Lilly, Janssen, Litebook Company Ltd., Lundbeck, Lundbeck Institute, Mathematics of Information Technology and Advanced Computing Systems, Michael Smith Foundation for Health Research, Servier, Takeda, UBC
Acknowledgments
CANMAT thanks the external reviewers: Murray W. Enns, MD, FRCPC (University of Manitoba), Glenda M. MacQueen, MD, PhD, FRCPC (University of Calgary) and Allan H. Young, MBChB, MPhil, PhD, FRCPsych (UK) (University of British Columbia).
References (147)
- et al.
Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression
Am. J. Geriatr. Psychiatry
(2008) - et al.
Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors
Clin. Ther.
(2007) - et al.
A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine
Biol. Psychiatry
(2002) - et al.
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
Lancet
(2009) - et al.
To combine or not to combine? A literature review of antidepressant combination therapy
J. Affect. Disord.
(2005) - et al.
Treatment for Adolescents with Depression Study (TADS): safety results
J. Am. Acad. Child Adolesc. Psych.
(2006) - et al.
Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder
Biol. Psychiatry
(2006) - et al.
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Lancet
(2003) - et al.
Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome
Drug Alcohol Depend.
(2009) - et al.
ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder
Prog. Neuropsychopharmacol. Biol. Psychiatry
(2008)
Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the treatment of management of major depressive disorder in adults
J. Affect. Disord.
Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies
J. Affect. Disord.
Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment
Am. J. Hum. Genet.
Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL
Biol. Psychiatry
Age may affect response to antidepressants with serotonergic and noradrenergic actions
J. Affect. Disord.
Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs
Biol. Psychiatry
Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies
Psychol. Med.
Meta-analytical studies on new antidepressants
Br. Med. Bull.
Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines
J. Psychopharmacol.
Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn
Pharmacoepidemiol. Drug Saf.
Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study
J. Clin. Psychiatry
Discontinuation symptoms in depression and anxiety disorders
Int. J. Neuropsychopharmacol.
Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies
CMAJ
Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression
Am. J. Psychiatry
Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes
J. Clin. Psychiatry
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study
J. Clin. Psychiatry
Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants
Br. J. Clin. Pharmacol.
The serotonin syndrome
N. Engl. J. Med.
Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data
Pharmacopsychiatry
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial
JAMA
The contribution of pharmacoepidemiology to the antidepressant-suicidality debate in children and adolescents
Int. Rev. Psychiatry
Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials
JAMA
Psychostimulants for depression
Cochrane Database Syst. Rev.
Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene
Science
Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn
N. Engl. J. Med.
Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? A systematic review and meta-analysis
J. Clin. Psychiatry
Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors
Int. J. Neuropsychopharmacol.
Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials
J. Clin. Psychiatry
Extended release quetiapine fumerate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study
J. Clin. Psychiatry
Current and emerging somatic treatment strategies in psychotic major depression
Expert. Rev. Neurother.
Double blind study of extended release quetiapine fumarate XR monotherapy for maintenance treatment of MDD (abstract)
Use of antidepressant combinations: which, when and why? Results of a Spanish survey
Acta Psychiatr. Scand., Suppl.
Venlafaxine (Effexor): concerns about increased risk of fatal outcomes in overdose
CMAJ
Suicidal behaviour in youths with depression treated with new-generation antidepressants: meta-analysis
Br. J. Psychiatry
Use of psychotropic medications in treating mood disorders during lactation: practical recommendations
CNS Drugs
Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies
Pharmacoepidemiol. Drug Saf.
Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo
J. Clin. Psychiatry
Antidepressant drug–drug interaction profile update
Drugs R & D
Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine
J. Clin. Psychopharmacol.
Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness
Ann. Clin. Psychiatry
Cited by (352)
Prevalence, clinical features and prescription patterns of psychotropic medications for patients with psychotic depression in China
2022, Journal of Affective DisordersEvaluating the efficacy and moderators of algorithm-guided antidepressant treatments of major depressive disorder
2022, Journal of Affective DisordersEfficacy of transcutaneous vagus nerve stimulation as treatment for depression: A systematic review
2021, Journal of Affective Disorders ReportsApplication of transcranial magnetic stimulation for major depression: Coil design and neuroanatomical variability considerations
2021, European Neuropsychopharmacology